ArticleBMC musculoskeletal disorders2026
Safety of intra-articular corticosteroid and hyaluronic acid injections: a 14-year population-based cohort study of 404,797 patients.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntra-articular corticosteroid and hyaluronic acid injections are fundamental in managing musculoskeletal pathologies. While their local efficacy is well documented, concerns regarding systemic safety, specifically the risk of acute hospitalization due to infection or vascular events—remain a subject of debate. This study aimed to evaluate long-term utilization trends and the incidence of subsequent hospitalizations in a large-scale general population.
methodsWe conducted a retrospective, population-based cohort study utilizing data from Clalit Health Services (Israel) between 2010 and 2023. The cohort included all adults (≥ 18 years) who received at least one intra-articular or peri-articular injection. The primary outcome was hospitalization within 30 days post-injection with a principal discharge diagnosis of a systemic/musculoskeletal infection or an acute vascular event. Multivariable logistic regression was used to identify independent predictors of adverse outcomes, adjusting for demographics, diabetes status, and Charlson Comorbidity Index (CCI).
resultsThe study analyzed 404,797 patients (mean age 55 ± 16 years, 55% female). Over the 14-year period, injection utilization rose significantly, with the standardized frequency doubling from 10.5 to 20.9 injections per 1,000 individuals (a 136% absolute increase). Despite this surge in volume, hospitalization rates remained low and stable throughout the study period. In multivariable analysis, the Charlson Comorbidity Index (CCI) was the sole independent predictor of hospitalization. Notably, diabetes mellitus alone was not associated with an increased risk of hospitalization.
conclusionCorticosteroid and hyaluronic acid injections remain a safe treatment option regarding the risk of severe adverse events requiring hospitalization. The risk of such events is rare and is primarily driven by the patient's comorbidity burden rather than the injection event itself. These findings support the continued use of these interventions, with an emphasis on individualized risk assessment using validated tools such as the Charlson Comorbidity Index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.